Vertex Pharmaceuticals Stock Jumps as Non-Opioid ... - Investopedia

Jan 31, 2025 · Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration. The drugmaker said the twice-daily pill, Journavx, is the first such …

CouponFollow Extension

11%
OFF

Vertex Stock: Vertex Pharmaceuticals Wins FDA Approval For Non …

2 weeks from now

Jan 31, 2025 · That could offer an aggressive entry into VRTX stock. ... Vertex Dives 11% On A 'Worst-Case Scenario' For Its Non-Opioid Pain Drug; Stock Market Today: Dow Jones Ends …

investors.com

$866
OFF

Vertex Pharmaceuticals Stock Rises As FDA Approves Its Pain Pill

2 weeks from now

Jan 31, 2025 · The FDA approved a new non-opioid painkiller. Its maker's stock is rising Journavx could bring in as much as $866 million in sales next year, according to one estimate

qz.com

31%
OFF

Vertex Pharmaceuticals Shares Gain After FDA Approves Non …

2 weeks from now

Shares of Vertex Pharmaceuticals VRTX5.31%increase; green up pointing triangle rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug …

wsj.com

6%
OFF

Vertex Stock Jumps After Non-Opioid Painkiller Gets FDA …

2 weeks from now

Jan 31, 2025 · Shares of Vertex Pharmaceuticals gained about 6% Friday morning, after the pharmaceutical company won U.S. approval for the first new non-opioid painkiller in decades. …

yahoo.com

FAQs about Vertex Pharmaceuticals Stock Jumps as Non-Opioid ... - Investopedia Coupon?

Why did Vertex Pharmaceuticals stock surge ahead of Friday's market open?

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment. It’s the first new class of pain treatment approved in more than 20 years, Vertex said in a press statement late Thursday. ...

Why was Vertex Pharmaceuticals' stock on track for an all-time high?

Vertex Pharmaceuticals' stock was on track for an all-time high Wednesday after the company released new data on its experimental non-opioid pain medicine. ...

Why is Vertex Pharmaceuticals (VRTX) stock rising?

Vertex Pharmaceuticals (VRTX) stock is rising following Food and Drug Administration (FDA) approval of Journavx, a non-opioid pain medication designed to treat moderate to severe acute pain. The new drug represents a potentially significant advancement in pain management, offering an alternative to traditional opioid-based treatments. ...

Is vertex a good stock to buy?

Vertex stock surged 5.7% to 499.88. Shares are forming a with a at 510.63, according to . But the stock is flirting with a downtrend line between 499.09 and 500.25, offering investors an early entry. The pain drug is far from Vertex's only catalyst in the near term. ...

Is Vertex Pharmaceuticals a good stock to buy in 2025?

Vertex Pharmaceuticals continues to execute its commercialization of three new drugs, JOURNAVX, CASGEVY, and ALYFTREK. Two of which have been approved by the FDA since December. Vertex's valuation appears high due to recent expenses, but analysts expect substantial earnings growth in 2025 as acquisition and clinical expenses subside. ...

Does Vertex Pharmaceuticals offer a treatment for painful nerve damage?

Vertex Pharmaceuticals is developing a treatment for painful nerve damage that can affect people with diabetes. This feature is powered by text-to-speech technology. Want to see it on more articles? ...